P
Philip LaRussa
Researcher at Columbia University
Publications - 126
Citations - 5702
Philip LaRussa is an academic researcher from Columbia University. The author has contributed to research in topics: Vaccination & Varicella vaccine. The author has an hindex of 38, co-authored 124 publications receiving 5344 citations. Previous affiliations of Philip LaRussa include Columbia University Medical Center & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1
William T. Shearer,Thomas C. Quinn,Philip LaRussa,Judy F. Lew,Lynne M. Mofenson,Susan Almy,Kenneth C. Rich,Edward Handelsman,Clemente Diaz,Marcello Pagano,Vincent L. Smeriglio,Leslie A. Kalish +11 more
TL;DR: In perinatally infected infants, HIV-1 RNA levels are high and decline only slowly during the first two years of life, which suggests that early treatment with antiretroviral agents may be indicated for these infants.
Journal ArticleDOI
The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group.
TL;DR: In children with leukemia who receive the live attenuated varicella vaccine, the subsequent incidence of zoster is lower than in children who have naturalvaricella infections.
Journal ArticleDOI
Effectiveness Over Time of Varicella Vaccine
Marietta Vázquez,Philip LaRussa,Anne A. Gershon,Linda M. Niccolai,Catherine E. Muehlenbein,Sharon Steinberg,Eugene D. Shapiro +6 more
TL;DR: Although varicella vaccine is effective, its effectiveness decreases significantly after 1 year, although most cases of breakthrough disease are mild, and the difference in effectiveness was not statistically significant for subsequent years.
Journal ArticleDOI
The postmarketing safety profile of varicella vaccine.
Robert G. Sharrar,Philip LaRussa,Susan A. Galea,Sharon Steinberg,Ann R. Sweet,R.Michael Keatley,Matthew E. Wells,Wendy P. Stephenson,Anne A. Gershon +8 more
TL;DR: The postmarketing safety profile of varicella vaccine was evaluated by analyzing selected adverse experience reports temporally associated with the administration of the vaccine as discussed by the authors, which were 7963 reports voluntarily submitted to Merck for an overall reporting rate of 5.0 per 10000 doses of vaccine distributed.
Journal ArticleDOI
The Safety Profile of Varicella Vaccine: A 10-Year Review
Susan A. Galea,Ann R. Sweet,Paul R. Beninger,Sharon Steinberg,Philip LaRussa,Anne A. Gershon,Robert G. Sharrar +6 more
TL;DR: The 10-year safety profile for Varivax is described using data submitted to Merck from routine global postmarketing surveillance and information from a Varicella Zoster Virus Identification Program, which uses polymerase chain reaction (PCR) analysis to identify the presence and strain of VZV in selected specimens.